Appendix 4C - Q1 FY23 Quarterly Cash Flow Report : vimarsana

First patient dosed in Phase 2 clinical trial for ATH434 in New Zealand, trial opens in Europe and AustraliaApproval of Investigational New Drug a...

Related Keywords

Italy , Melbourne , Victoria , Australia , United States , New Zealand , United Kingdom , California , San Francisco , Italian , American , David Stamler , National Institute Of Health , American Neurological Association Annual Meeting , System Atrophy Coalition , Nasdaq , Health Biotech , Italian Medicines Agency , Alterity Therapeutics , Movement Disorders , Company Phase , Company American Depositary Shares Adss , Prnewswire Alterity Therapeutics Limited , Drug Administration , European Commission , International Congress , Listing Qualifications Department Of Nasdaq , Investigational New Drug , Therapeutics Limited , Quarterly Cash Flow Report , Multiple System Atrophy , Executive Officer David Stamler , Agenzia Italiana Del Farmaco , History Study , Quantitative Motor Assessments , Multiple System , Learning Segmentation Improves Precision , Volume Assessment , Subcortical Structures , Micro Cap Virtual Conference , Stockhead Investor Guide , Multiple System Atrophy Coalition , Family Conference , Listing Qualifications Department , American Depositary Shares , Nasdaq Global , System Atrophy , Neurological Disorders , Multiple System Atrophy Fact ,